211 related articles for article (PubMed ID: 1718035)
21. The CR2/CD19 complex on human B cells contains the src-family kinase Lyn.
van Noesel CJ; Lankester AC; van Schijndel GM; van Lier RA
Int Immunol; 1993 Jul; 5(7):699-705. PubMed ID: 7690241
[TBL] [Abstract][Full Text] [Related]
22. The role of C3 and its fragments in the control of S phase entry of activated mouse B lymphocytes via the complement receptor type 2.
Lernhardt W; Melchers F
Exp Clin Immunogenet; 1988; 5(2-3):115-22. PubMed ID: 2978811
[TBL] [Abstract][Full Text] [Related]
23. Monovalent ligands of complement receptor 2 inhibit whereas polyvalent ligands enhance anti-Ig-induced human B cell intracytoplasmic free calcium concentration.
Tsokos GC; Lambris JD; Finkelman FD; Anastassiou ED; June CH
J Immunol; 1990 Mar; 144(5):1640-5. PubMed ID: 2137840
[TBL] [Abstract][Full Text] [Related]
24. Modulation of mouse complement receptors 1 and 2 suppresses antibody responses in vivo.
Thyphronitis G; Kinoshita T; Inoue K; Schweinle JE; Tsokos GC; Metcalf ES; Finkelman FD; Balow JE
J Immunol; 1991 Jul; 147(1):224-30. PubMed ID: 1828822
[TBL] [Abstract][Full Text] [Related]
25. A new mouse anti-mouse complement receptor type 2 and 1 (CR2/CR1) monoclonal antibody as a tool to study receptor involvement in chronic models of immune responses and disease.
Kulik L; Hewitt FB; Willis VC; Rodriguez R; Tomlinson S; Holers VM
Mol Immunol; 2015 Feb; 63(2):479-88. PubMed ID: 25457881
[TBL] [Abstract][Full Text] [Related]
26. CD19 has a potential CD77 (globotriaosyl ceramide)-binding site with sequence similarity to verotoxin B-subunits: implications of molecular mimicry for B cell adhesion and enterohemorrhagic Escherichia coli pathogenesis.
Maloney MD; Lingwood CA
J Exp Med; 1994 Jul; 180(1):191-201. PubMed ID: 7516406
[TBL] [Abstract][Full Text] [Related]
27. The CR2 receptor (CD21) shows increased expression in the more differentiated cells of an antigen-specific B cell line.
Pillemer SR; Tsokos GC; Barbieri SA; Balow JE; Golding B
Cell Immunol; 1990 Feb; 125(2):386-95. PubMed ID: 1688740
[TBL] [Abstract][Full Text] [Related]
28. Mapping of the C3b-binding site of CR1 and construction of a (CR1)2-F(ab')2 chimeric complement inhibitor.
Kalli KR; Hsu PH; Bartow TJ; Ahearn JM; Matsumoto AK; Klickstein LB; Fearon DT
J Exp Med; 1991 Dec; 174(6):1451-60. PubMed ID: 1836011
[TBL] [Abstract][Full Text] [Related]
29. CR2 ligands modulate human B cell activation.
Bohnsack JF; Cooper NR
J Immunol; 1988 Oct; 141(8):2569-76. PubMed ID: 2459218
[TBL] [Abstract][Full Text] [Related]
30. Cross-linking CD21/CD35 or CD19 increases both B7-1 and B7-2 expression on murine splenic B cells.
Kozono Y; Abe R; Kozono H; Kelly RG; Azuma T; Holers VM
J Immunol; 1998 Feb; 160(4):1565-72. PubMed ID: 9469411
[TBL] [Abstract][Full Text] [Related]
31. Complement component C3d-antigen complexes can either augment or inhibit B lymphocyte activation and humoral immunity in mice depending on the degree of CD21/CD19 complex engagement.
Lee Y; Haas KM; Gor DO; Ding X; Karp DR; Greenspan NS; Poe JC; Tedder TF
J Immunol; 2005 Dec; 175(12):8011-23. PubMed ID: 16339538
[TBL] [Abstract][Full Text] [Related]
32. Soluble recombinant CR2 (CD21) inhibits Epstein-Barr virus infection.
Nemerow GR; Mullen JJ; Dickson PW; Cooper NR
J Virol; 1990 Mar; 64(3):1348-52. PubMed ID: 2154612
[TBL] [Abstract][Full Text] [Related]
33. Signaling through the EBV/C3d receptor (CR2, CD21) in human B lymphocytes: activation of phosphatidylinositol 3-kinase via a CD19-independent pathway.
Bouillie S; Barel M; Frade R
J Immunol; 1999 Jan; 162(1):136-43. PubMed ID: 9886379
[TBL] [Abstract][Full Text] [Related]
34. Expression of human complement receptor 2 (CR2, CD21) in Cr2-/- mice restores humoral immune function.
Marchbank KJ; Watson CC; Ritsema DF; Holers VM
J Immunol; 2000 Sep; 165(5):2354-61. PubMed ID: 10946257
[TBL] [Abstract][Full Text] [Related]
35. Enhancement of antibody-dependent mechanisms of tumor cell lysis by a targeted activator of complement.
Imai M; Ohta R; Varela JC; Song H; Tomlinson S
Cancer Res; 2007 Oct; 67(19):9535-41. PubMed ID: 17909064
[TBL] [Abstract][Full Text] [Related]
36. Expression of functional human Epstein-Barr virus/C3d receptor ([CR2] CD21) on insulinoma cell line. Induction of tumor rejection but not diabetes in syngeneic rats.
Carel JC; Holers VM; Chick WL; Littman D; Lacy PE
Diabetes; 1991 Jul; 40(7):809-14. PubMed ID: 1647992
[TBL] [Abstract][Full Text] [Related]
37. Characterization of the human complement receptor 2 (CR2, CD21) promoter reveals sequences shared with regulatory regions of other developmentally restricted B cell proteins.
Rayhel EJ; Dehoff MH; Holers VM
J Immunol; 1991 Mar; 146(6):2021-6. PubMed ID: 1706386
[TBL] [Abstract][Full Text] [Related]
38. Identification of a partial cDNA clone for the C3d/Epstein-Barr virus receptor of human B lymphocytes: homology with the receptor for fragments C3b and C4b of the third and fourth components of complement.
Weis JJ; Fearon DT; Klickstein LB; Wong WW; Richards SA; de Bruyn Kops A; Smith JA; Weis JH
Proc Natl Acad Sci U S A; 1986 Aug; 83(15):5639-43. PubMed ID: 3016712
[TBL] [Abstract][Full Text] [Related]
39. A molecular and immunochemical characterization of mouse CR2. Evidence for a single gene model of mouse complement receptors 1 and 2.
Molina H; Kinoshita T; Inoue K; Carel JC; Holers VM
J Immunol; 1990 Nov; 145(9):2974-83. PubMed ID: 2145366
[TBL] [Abstract][Full Text] [Related]
40. CD19 signaling pathways play a major role for murine AIDS induction and progression.
Knoetig SM; Torrey TA; Naghashfar Z; McCarty T; Morse HC
J Immunol; 2002 Nov; 169(10):5607-14. PubMed ID: 12421939
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
